VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Synchotrope TA2M Vaccine
Vaccine Information
  • Vaccine Name: Synchotrope TA2M Vaccine
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Vaccine Ontology ID: VO_0007108
  • Type: Recombinant plasmid DNA vaccine
  • Status: Research
  • Immunization Route: Intramuscular injection (i.m.)
  • Description: This is for Melanoma Cancer (NCT00023647). A recombinant plasmid DNA vaccine that encodes two peptides, tyrosinase 207–216 and tyrosinase 1–17, both of which are derived from human tyrosinase (Tagawa et al., 2003).
Host Response

Human Response

  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: There were no or minimal responses to the epitopes tyrosinase 1–9 and tyrosinase 8 –17 by tetramer assay (Tagawa et al., 2003).
References
NCT00023647: [https://clinicaltrials.gov/show/NCT00023647]
Tagawa et al., 2003: Tagawa ST, Lee P, Snively J, Boswell W, Ounpraseuth S, Lee S, Hickingbottom B, Smith J, Johnson D, Weber JS. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma. Cancer. 2003; 98(1); 144-154. [PubMed: 12833467].